Recent financial and corporate developments shape the biotech industry’s trajectory. Kriya Therapeutics secured $313 million to advance gene therapies targeting chronic diseases despite emerging concerns over viral vectors. Calidi Biotherapeutics closed a $6.9 million offering, and QuidelOrtho finalized $3.4 billion in debt refinancing, signaling financial agility. Industry leadership shifts include executive appointments at Illumina, QuidelOrtho, Myriad Genetics, and Andrew Eldridge’s CFO hiring at Abcuro. Gilead expanded in vivo cell therapy capabilities via a $350 million Interius acquisition, consolidating its position in the emerging therapeutic approach.